TimesMachine is an exclusive benefit for home delivery and digital subscribers. Full text is unavailable for this digitized archive article. Subscribers may view the full text of this article in ...

Just three years ago, Circassia was riding high, raising £200 million ($285 million) from its initial public offering (IPO), making it the most successful European biotech stock launch ever.

UK biotech Circassia has finally given up on its allergy drug development business, citing difficulties in overcoming a strong placebo effect in the trials required for approval by regulators.

As for the allergy division, things are largely at a standstill. Finances are being redirected into respiratory and all trials other than the final dust-mite allergy study - due to announce results in ...

New oil and gas assets in Nigeria promise to send production through the roof – but the ris ...

MAIKOP, January 10, 22:18 /ITAR-TASS/. Bella Kukan, AdygeI’s winner of the first festival pageant Miss Circassia has a firm intention to participate in peacekeeping missions in Syria.

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...